Over a week ago
Conference/Events
39th Annual Healthcare…
39th Annual Healthcare Virtual Conference will be held on January 11-14.
Show Hide Related Items >> <<
12/01/20 Zymeworks expands zanidatamab trial in HER2 in amplified biliary tract cancer 11/30/20 Zymeworks gets FDA breakthrough therapy designation for zanidatamab 11/19/20 Zymeworks receives orphan drug designation for zanidatamab 11/16/20 ALX Oncology, Zymeworks partner to evaluate zanidatamab-ALX148 combo 01/13/21 Sarepta, Genevant announce collaboration for gene editing therapeutics 01/07/21 Sarepta drops 52% to $80.00 after Study SRP-9001-102 results 01/07/21 Sarepta trading resumes 01/07/21 Sarepta announces Study SRP-9001-102 meets primary biological endpoint 12/18/20 Sotera Health announces debt pay down, expansion of revolving credit facility 12/22/20 Revance and Ajinomoto announce strategic commercial manufacturing agreement 12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues 01/11/21 Rubius Therapeutics announces anticipated 2021 catalysts, objectives 01/11/21 Rubius Therapeutics announces clinical program updates 12/14/20 Rubius Therapeutics trading resumes 12/14/20 Rubius Therapeutics trading halted, volatility trading pause 12/09/20 Pacira reports preliminary November net product sales $38.9M 11/18/20 Pacira receives European Commission approval for EXPAREL 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/11/20 Pacira reports preliminary October net product sales $41.7M 10/29/20 Nano-X Imaging signs with Ambra Health to enable image access, transfer 10/02/20 Nano-X Imaging soars 33% after announcing live technology demonstration 09/23/20 Nano-X Imaging appoints Gilad Yron as CBO 09/22/20 Nano-X slides as another prominent short-seller calls it 'piece of garbage' 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 12/04/20 Morphic Holding appoints Martin Edwards to board of directors 11/09/20 Morphic Holding expects cash to be sufficient through end of 2022 09/23/20 Morphic Holding: First volunteers dosed in Phase 1 trial of MORF-057 01/11/21 HealthEquity expects 5.7M-5.8M HSA members by Jan. 31 12/21/20 Exelixis announces cabozantinib trial meets co-primary endpoint 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact $26.94 / -3.335 (-11.02%)
01/13/21 Esperion sees FY21 operating expenses approximately $320M-$340M 01/13/21 Esperion sees Q4 U.S. net product revenue $8M-$8.5M 12/16/20 Daiichi Sankyo, Esperion announce Swissmedic approval for LDL-C treatment 12/15/20 Esperion appoints Sheldon Koenig as COO; CCO Mark Glickman to leave 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AGIO Agios Pharmaceuticals 01/11/21 Agios Pharmaceuticals expects cash to fund requirements to end of 2022 01/11/21 Agios Pharmaceuticals announces 2025 strategic vision 01/11/21 Agios Pharmaceuticals announces anticipated 2021 key milestones 12/21/20 Agios Pharmaceuticals expects results from ACTIVATE-T study in Q1 01/07/21 Abiomed surpasses more than 1,000 patents worldwide 12/21/20 Abiomed says first two patients treated with Abiomed Breethe OXY-1 System 12/15/20 Abiomed completes Impella ECP EFS first stage, gets 510 clearance for XR sheath 12/14/20 Abiomed receives 510(k) clearance from FDA for XR sheath set 12/21/20 SVB Leerink Abiomed price target raised to $320 from $280 at SVB Leerink 12/14/20 Piper Sandler Abiomed gets approval for XR sheath, says Piper Sandler 10/20/20 Piper Sandler Abiomed's TCT presentation highlights solid existing data, says Piper Sandler 08/07/20 SVB Leerink Abiomed price target raised to $335 from $280 at SVB Leerink AGIO Agios Pharmaceuticals 12/23/20 Citi Agios shares 'significantly undervalued at this point,' says Citi 12/22/20 SVB Leerink Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink 12/22/20 Cantor Fitzgerald Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald 12/22/20 Barclays Agios could enter 2022 with a third fewer shares, says Barclays 01/07/21 Canaccord AdaptHealth price target raised to $50 from $39 at Canaccord 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 01/11/21 JPMorgan BioAtla initiated with an Overweight at JPMorgan 01/11/21 Credit Suisse BioAtla initiated with an Outperform at Credit Suisse 01/11/21 Jefferies BioAtla initiated with a Buy at Jefferies 01/11/21 BTIG BioAtla initiated with a Buy at BTIG 10/23/20 SVB Leerink NextGen Healthcare price target raised to $14 from $12 at SVB Leerink 10/23/20 Piper Sandler NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler 07/31/20 Piper Sandler NextGen Healthcare price target raised to $23 from $17 at Piper Sandler 06/02/20 Deutsche Bank NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank 12/14/20 JPMorgan Olema Oncology initiated with an Overweight at JPMorgan 12/14/20 Jefferies Olema Pharmaceuticals initiated with a Buy at Jefferies 12/14/20 Canaccord Olema Pharmaceuticals initiated with a Buy at Canaccord 12/14/20 Cowen Olema Pharmaceuticals initiated with an Outperform at Cowen 01/06/21 RBC Capital Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas 12/14/20 Barclays Pacira price target raised to $79 from $73 at Barclays 09/30/20 Jefferies Pacira price target raised to $75 from $69 at Jefferies 09/21/20 Northland Pacira upgraded to Outperform on Exparel sales expectations at Northland 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James $26.94 / -3.335 (-11.02%)
11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi 12/14/20 William Blair Calithera risk/reward attractive into CANTATA readout, says William Blair 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 01/06/21 BTIG HealthEquity initiated with a Neutral at BTIG 01/06/21 Deutsche Bank HealthEquity price target raised to $77 from $60 at Deutsche Bank 12/08/20 Cantor Fitzgerald HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald 12/08/20 JPMorgan HealthEquity price target raised to $72 from $61 at JPMorgan 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital 09/15/20 Cantor Fitzgerald Cantor reiterates $70 target on Nano-X after 'unfounded' short report 09/15/20 Cantor Fitzgerald Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald 09/15/20 Oppenheimer Nano-X Imaging initiated with a Perform at Oppenheimer 09/15/20 Berenberg Nano-X Imaging initiated with a Buy at Berenberg 01/12/21 Citi Sarepta downgraded to Neutral from Buy at Citi 01/11/21 Fly Intel: Top five analyst downgrades 01/11/21 UBS Sarepta downgraded to Neutral on 'unexpected negative' results at UBS 01/11/21 UBS Sarepta downgraded to Neutral from Buy at UBS 01/13/21 Baird Sotera Health initiated with an Outperform at Baird 12/15/20 KeyBanc Sotera Health initiated with an Overweight at KeyBanc 12/15/20 JPMorgan Sotera Health initiated with an Overweight at JPMorgan 12/15/20 Jefferies Sotera Health initiated with a Buy at Jefferies 12/29/20 Needham Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/14/20 JPMorgan Rubius Therapeutics resumed with a Neutral at JPMorgan 03/13/20 Morgan Stanley Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program 03/13/20 Guggenheim Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim 03/13/20 SVB Leerink Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation 01/12/21 SVB Leerink Zymeworks price target raised to $66 from $45 at SVB Leerink 01/12/21 Wells Fargo Zymeworks price target raised to $71 from $58 at Wells Fargo 09/29/20 JPMorgan Zymeworks resumed with a Neutral at JPMorgan 08/06/20 Fly Intel: Top analyst initiations 11/03/20 Zymeworks reports Q3 EPS ($1.43), consensus (67c) 08/05/20 Zymeworks reports Q2 EPS (77c), consensus (67c) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) 08/05/20 Sarepta reports Q2 EPS ($1.51), consensus ($1.76) 01/11/21 Sotera Health reports preliminary 2020 revenue $817M, consensus $814.05M 01/11/21 Sotera Health reports preliminary Q4 revenue $216M, consensus $206.91M 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) 11/09/20 Rubius Therapeutics reports Q3 EPS (51c), consensus (49c) 08/10/20 Rubius Therapeutics reports Q2 EPS (47c), consensus (50c) 01/07/21 Pacira reports 2020 revenue $429.6M, consensus $427.7M 10/29/20 Pacira reports Q3 adj. EPS 68c, consensus 63c 10/07/20 Pacira reports preliminary Q3 net product sales of $116.9M, consensus $111.86M 08/06/20 Pacira reports preliminary July sales of Exparel of $38.1M 01/13/21 NextGen Healthcare sees FY21 EPS 92c-98c, consensus 89c 01/13/21 NextGen Healthcare sees Q3 EPS 24c-26c, consensus 19c 10/22/20 NextGen Healthcare reinstates FY21 EPS outlook 83c-93c, consensus 83c 10/22/20 NextGen Healthcare reports Q2 EPS 30c, consensus 20c 11/09/20 Nano-X Imaging reports Q3 EPS (29c), two est. (23c) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 08/10/20 Morphic Holding reports Q2 EPS (52c), consensus (56c) 12/07/20 HealthEquity raises FY21 EPS view to $1.55-$1.61 from $1.48-$1.58 12/07/20 HealthEquity reports Q3 EPS 41c, consensus 36c 12/07/20 Notable companies reporting after market close 09/08/20 HealthEquity sees FY21 EPS $1.48-$1.58, consensus $1.44 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c $26.94 / -3.335 (-11.02%)
08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c AGIO Agios Pharmaceuticals 11/05/20 Agios Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.31) 07/30/20 Agios Pharmaceuticals reports Q2 EPS ($1.31), consensus ($1.37) 10/29/20 Abiomed sees Q3 revenue $221M-$230M, consensus $234.29M 10/29/20 Abiomed reports Q2 EPS $1.36, consensus 92c 08/06/20 Abiomed not providing guidance due to COVID-19 08/06/20 Abiomed reports Q1 EPS 98c, consensus 29c
Conference/Events
39th Annual Healthcare…
39th Annual Healthcare Virtual Conference will be held on January 11-14.
Show Hide Related Items >> <<
12/01/20 Zymeworks expands zanidatamab trial in HER2 in amplified biliary tract cancer 11/30/20 Zymeworks gets FDA breakthrough therapy designation for zanidatamab 11/19/20 Zymeworks receives orphan drug designation for zanidatamab 11/16/20 ALX Oncology, Zymeworks partner to evaluate zanidatamab-ALX148 combo 01/07/21 Sarepta drops 52% to $80.00 after Study SRP-9001-102 results 01/07/21 Sarepta trading resumes 01/07/21 Sarepta announces Study SRP-9001-102 meets primary biological endpoint 01/07/21 Sarepta trading halted, news pending 12/18/20 Sotera Health announces debt pay down, expansion of revolving credit facility 12/22/20 Revance and Ajinomoto announce strategic commercial manufacturing agreement 12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues 01/11/21 Rubius Therapeutics announces anticipated 2021 catalysts, objectives 01/11/21 Rubius Therapeutics announces clinical program updates 12/14/20 Rubius Therapeutics trading resumes 12/14/20 Rubius Therapeutics trading halted, volatility trading pause 12/09/20 Pacira reports preliminary November net product sales $38.9M 11/18/20 Pacira receives European Commission approval for EXPAREL 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/11/20 Pacira reports preliminary October net product sales $41.7M 10/29/20 Nano-X Imaging signs with Ambra Health to enable image access, transfer 10/02/20 Nano-X Imaging soars 33% after announcing live technology demonstration 09/23/20 Nano-X Imaging appoints Gilad Yron as CBO 09/22/20 Nano-X slides as another prominent short-seller calls it 'piece of garbage' 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 12/04/20 Morphic Holding appoints Martin Edwards to board of directors 11/09/20 Morphic Holding expects cash to be sufficient through end of 2022 09/23/20 Morphic Holding: First volunteers dosed in Phase 1 trial of MORF-057 01/11/21 HealthEquity expects 5.7M-5.8M HSA members by Jan. 31 12/21/20 Exelixis announces cabozantinib trial meets co-primary endpoint 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact 12/16/20 Daiichi Sankyo, Esperion announce Swissmedic approval for LDL-C treatment 12/15/20 Esperion appoints Sheldon Koenig as COO; CCO Mark Glickman to leave 11/13/20 Esperion announces results of pooled data from Phase 3 trials of NEXLETOL 10/07/20 Esperion announces results from Phase 3 trials of NEXLETOL Tablets 01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AGIO Agios Pharmaceuticals 01/11/21 Agios Pharmaceuticals expects cash to fund requirements to end of 2022 01/11/21 Agios Pharmaceuticals announces 2025 strategic vision 01/11/21 Agios Pharmaceuticals announces anticipated 2021 key milestones 12/21/20 Agios Pharmaceuticals expects results from ACTIVATE-T study in Q1 01/07/21 Abiomed surpasses more than 1,000 patents worldwide 12/21/20 Abiomed says first two patients treated with Abiomed Breethe OXY-1 System 12/15/20 Abiomed completes Impella ECP EFS first stage, gets 510 clearance for XR sheath 12/14/20 Abiomed receives 510(k) clearance from FDA for XR sheath set 12/21/20 SVB Leerink Abiomed price target raised to $320 from $280 at SVB Leerink 12/14/20 Piper Sandler Abiomed gets approval for XR sheath, says Piper Sandler 10/20/20 Piper Sandler Abiomed's TCT presentation highlights solid existing data, says Piper Sandler 08/07/20 SVB Leerink Abiomed price target raised to $335 from $280 at SVB Leerink AGIO Agios Pharmaceuticals 12/23/20 Citi Agios shares 'significantly undervalued at this point,' says Citi 12/22/20 SVB Leerink Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink 12/22/20 Cantor Fitzgerald Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald 12/22/20 Barclays Agios could enter 2022 with a third fewer shares, says Barclays 01/07/21 Canaccord AdaptHealth price target raised to $50 from $39 at Canaccord 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 01/11/21 JPMorgan BioAtla initiated with an Overweight at JPMorgan 01/11/21 Credit Suisse BioAtla initiated with an Outperform at Credit Suisse 01/11/21 Jefferies BioAtla initiated with a Buy at Jefferies 01/11/21 BTIG BioAtla initiated with a Buy at BTIG 10/23/20 SVB Leerink NextGen Healthcare price target raised to $14 from $12 at SVB Leerink 10/23/20 Piper Sandler NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler 07/31/20 Piper Sandler NextGen Healthcare price target raised to $23 from $17 at Piper Sandler 06/02/20 Deutsche Bank NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank 12/14/20 JPMorgan Olema Oncology initiated with an Overweight at JPMorgan 12/14/20 Jefferies Olema Pharmaceuticals initiated with a Buy at Jefferies 12/14/20 Canaccord Olema Pharmaceuticals initiated with a Buy at Canaccord 12/14/20 Cowen Olema Pharmaceuticals initiated with an Outperform at Cowen 01/06/21 RBC Capital Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas 12/14/20 Barclays Pacira price target raised to $79 from $73 at Barclays 09/30/20 Jefferies Pacira price target raised to $75 from $69 at Jefferies 09/21/20 Northland Pacira upgraded to Outperform on Exparel sales expectations at Northland 01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi 12/14/20 William Blair Calithera risk/reward attractive into CANTATA readout, says William Blair 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 01/06/21 BTIG HealthEquity initiated with a Neutral at BTIG 01/06/21 Deutsche Bank HealthEquity price target raised to $77 from $60 at Deutsche Bank 12/08/20 Cantor Fitzgerald HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald 12/08/20 JPMorgan HealthEquity price target raised to $72 from $61 at JPMorgan 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital 09/15/20 Cantor Fitzgerald Cantor reiterates $70 target on Nano-X after 'unfounded' short report 09/15/20 Cantor Fitzgerald Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald 09/15/20 Oppenheimer Nano-X Imaging initiated with a Perform at Oppenheimer 09/15/20 Berenberg Nano-X Imaging initiated with a Buy at Berenberg 01/12/21 Citi Sarepta downgraded to Neutral from Buy at Citi 01/11/21 Fly Intel: Top five analyst downgrades 01/11/21 UBS Sarepta downgraded to Neutral on 'unexpected negative' results at UBS 01/11/21 UBS Sarepta downgraded to Neutral from Buy at UBS 12/15/20 KeyBanc Sotera Health initiated with an Overweight at KeyBanc 12/15/20 JPMorgan Sotera Health initiated with an Overweight at JPMorgan 12/15/20 Jefferies Sotera Health initiated with a Buy at Jefferies 12/15/20 Citi Sotera Health initiated with a Buy at Citi 12/29/20 Needham Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/14/20 JPMorgan Rubius Therapeutics resumed with a Neutral at JPMorgan 03/13/20 Morgan Stanley Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program 03/13/20 Guggenheim Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim 03/13/20 SVB Leerink Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation 01/12/21 SVB Leerink Zymeworks price target raised to $66 from $45 at SVB Leerink 01/12/21 Wells Fargo Zymeworks price target raised to $71 from $58 at Wells Fargo 09/29/20 JPMorgan Zymeworks resumed with a Neutral at JPMorgan 08/06/20 Fly Intel: Top analyst initiations 11/03/20 Zymeworks reports Q3 EPS ($1.43), consensus (67c) 08/05/20 Zymeworks reports Q2 EPS (77c), consensus (67c) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) 08/05/20 Sarepta reports Q2 EPS ($1.51), consensus ($1.76) 01/11/21 Sotera Health reports preliminary 2020 revenue $817M, consensus $814.05M 01/11/21 Sotera Health reports preliminary Q4 revenue $216M, consensus $206.91M 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) 11/09/20 Rubius Therapeutics reports Q3 EPS (51c), consensus (49c) 08/10/20 Rubius Therapeutics reports Q2 EPS (47c), consensus (50c) 01/07/21 Pacira reports 2020 revenue $429.6M, consensus $427.7M 10/29/20 Pacira reports Q3 adj. EPS 68c, consensus 63c 10/07/20 Pacira reports preliminary Q3 net product sales of $116.9M, consensus $111.86M 08/06/20 Pacira reports preliminary July sales of Exparel of $38.1M 10/22/20 NextGen Healthcare reinstates FY21 EPS outlook 83c-93c, consensus 83c 10/22/20 NextGen Healthcare reports Q2 EPS 30c, consensus 20c 07/30/20 NextGen Healthcare not providing FY21 guidance 07/30/20 NextGen Healthcare reports Q1 EPS 21c, consensus 8c 11/09/20 Nano-X Imaging reports Q3 EPS (29c), two est. (23c) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 08/10/20 Morphic Holding reports Q2 EPS (52c), consensus (56c) 12/07/20 HealthEquity raises FY21 EPS view to $1.55-$1.61 from $1.48-$1.58 12/07/20 HealthEquity reports Q3 EPS 41c, consensus 36c 12/07/20 Notable companies reporting after market close 09/08/20 HealthEquity sees FY21 EPS $1.48-$1.58, consensus $1.44 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c AGIO Agios Pharmaceuticals 11/05/20 Agios Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.31) 07/30/20 Agios Pharmaceuticals reports Q2 EPS ($1.31), consensus ($1.37) 10/29/20 Abiomed sees Q3 revenue $221M-$230M, consensus $234.29M 10/29/20 Abiomed reports Q2 EPS $1.36, consensus 92c 08/06/20 Abiomed not providing guidance due to COVID-19 08/06/20 Abiomed reports Q1 EPS 98c, consensus 29c
Conference/Events
39th Annual Healthcare…
39th Annual Healthcare Virtual Conference will be held on January 11-14.
Show Hide Related Items >> <<
12/01/20 Zymeworks expands zanidatamab trial in HER2 in amplified biliary tract cancer 11/30/20 Zymeworks gets FDA breakthrough therapy designation for zanidatamab 11/19/20 Zymeworks receives orphan drug designation for zanidatamab 11/16/20 ALX Oncology, Zymeworks partner to evaluate zanidatamab-ALX148 combo 01/07/21 Sarepta drops 52% to $80.00 after Study SRP-9001-102 results 01/07/21 Sarepta trading resumes 01/07/21 Sarepta announces Study SRP-9001-102 meets primary biological endpoint 01/07/21 Sarepta trading halted, news pending 12/18/20 Sotera Health announces debt pay down, expansion of revolving credit facility 12/22/20 Revance and Ajinomoto announce strategic commercial manufacturing agreement 12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues 01/11/21 Rubius Therapeutics announces anticipated 2021 catalysts, objectives 01/11/21 Rubius Therapeutics announces clinical program updates 12/14/20 Rubius Therapeutics trading resumes 12/14/20 Rubius Therapeutics trading halted, volatility trading pause 12/09/20 Pacira reports preliminary November net product sales $38.9M 11/18/20 Pacira receives European Commission approval for EXPAREL 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/11/20 Pacira reports preliminary October net product sales $41.7M 10/29/20 Nano-X Imaging signs with Ambra Health to enable image access, transfer 10/02/20 Nano-X Imaging soars 33% after announcing live technology demonstration 09/23/20 Nano-X Imaging appoints Gilad Yron as CBO 09/22/20 Nano-X slides as another prominent short-seller calls it 'piece of garbage' 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 12/04/20 Morphic Holding appoints Martin Edwards to board of directors 11/09/20 Morphic Holding expects cash to be sufficient through end of 2022 09/23/20 Morphic Holding: First volunteers dosed in Phase 1 trial of MORF-057 01/11/21 HealthEquity expects 5.7M-5.8M HSA members by Jan. 31 12/21/20 Exelixis announces cabozantinib trial meets co-primary endpoint 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact 12/16/20 Daiichi Sankyo, Esperion announce Swissmedic approval for LDL-C treatment 12/15/20 Esperion appoints Sheldon Koenig as COO; CCO Mark Glickman to leave 11/13/20 Esperion announces results of pooled data from Phase 3 trials of NEXLETOL 10/07/20 Esperion announces results from Phase 3 trials of NEXLETOL Tablets $267.53 / +15.17 (+6.01%)
01/11/21 AC Immune, Biogen rise after Lilly reports Alzheimer's study met endpoint 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AGIO Agios Pharmaceuticals 01/11/21 Agios Pharmaceuticals expects cash to fund requirements to end of 2022 01/11/21 Agios Pharmaceuticals announces 2025 strategic vision 01/11/21 Agios Pharmaceuticals announces anticipated 2021 key milestones 12/21/20 Agios Pharmaceuticals expects results from ACTIVATE-T study in Q1 01/07/21 Abiomed surpasses more than 1,000 patents worldwide 12/21/20 Abiomed says first two patients treated with Abiomed Breethe OXY-1 System 12/15/20 Abiomed completes Impella ECP EFS first stage, gets 510 clearance for XR sheath 12/14/20 Abiomed receives 510(k) clearance from FDA for XR sheath set 12/21/20 SVB Leerink Abiomed price target raised to $320 from $280 at SVB Leerink 12/14/20 Piper Sandler Abiomed gets approval for XR sheath, says Piper Sandler 10/20/20 Piper Sandler Abiomed's TCT presentation highlights solid existing data, says Piper Sandler 08/07/20 SVB Leerink Abiomed price target raised to $335 from $280 at SVB Leerink AGIO Agios Pharmaceuticals 12/23/20 Citi Agios shares 'significantly undervalued at this point,' says Citi 12/22/20 SVB Leerink Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink 12/22/20 Cantor Fitzgerald Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald 12/22/20 Barclays Agios could enter 2022 with a third fewer shares, says Barclays 01/07/21 Canaccord AdaptHealth price target raised to $50 from $39 at Canaccord 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 01/11/21 JPMorgan BioAtla initiated with an Overweight at JPMorgan 01/11/21 Credit Suisse BioAtla initiated with an Outperform at Credit Suisse 01/11/21 Jefferies BioAtla initiated with a Buy at Jefferies 01/11/21 BTIG BioAtla initiated with a Buy at BTIG 10/23/20 SVB Leerink NextGen Healthcare price target raised to $14 from $12 at SVB Leerink 10/23/20 Piper Sandler NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler 07/31/20 Piper Sandler NextGen Healthcare price target raised to $23 from $17 at Piper Sandler 06/02/20 Deutsche Bank NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank 12/14/20 JPMorgan Olema Oncology initiated with an Overweight at JPMorgan 12/14/20 Jefferies Olema Pharmaceuticals initiated with a Buy at Jefferies 12/14/20 Canaccord Olema Pharmaceuticals initiated with a Buy at Canaccord 12/14/20 Cowen Olema Pharmaceuticals initiated with an Outperform at Cowen 01/06/21 RBC Capital Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas 12/14/20 Barclays Pacira price target raised to $79 from $73 at Barclays 09/30/20 Jefferies Pacira price target raised to $75 from $69 at Jefferies 09/21/20 Northland Pacira upgraded to Outperform on Exparel sales expectations at Northland $267.53 / +15.17 (+6.01%)
01/11/21 Goldman Sachs Eli Lilly's Alzheimer's trial data a 'positive surprise,' says Goldman Sachs 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi 12/14/20 William Blair Calithera risk/reward attractive into CANTATA readout, says William Blair 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 01/06/21 BTIG HealthEquity initiated with a Neutral at BTIG 01/06/21 Deutsche Bank HealthEquity price target raised to $77 from $60 at Deutsche Bank 12/08/20 Cantor Fitzgerald HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald 12/08/20 JPMorgan HealthEquity price target raised to $72 from $61 at JPMorgan 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital 09/15/20 Cantor Fitzgerald Cantor reiterates $70 target on Nano-X after 'unfounded' short report 09/15/20 Cantor Fitzgerald Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald 09/15/20 Oppenheimer Nano-X Imaging initiated with a Perform at Oppenheimer 09/15/20 Berenberg Nano-X Imaging initiated with a Buy at Berenberg 01/11/21 Fly Intel: Top five analyst downgrades 01/11/21 UBS Sarepta downgraded to Neutral on 'unexpected negative' results at UBS 01/11/21 UBS Sarepta downgraded to Neutral from Buy at UBS 01/08/21 Chardan Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan 12/15/20 KeyBanc Sotera Health initiated with an Overweight at KeyBanc 12/15/20 JPMorgan Sotera Health initiated with an Overweight at JPMorgan 12/15/20 Jefferies Sotera Health initiated with a Buy at Jefferies 12/15/20 Citi Sotera Health initiated with a Buy at Citi 12/29/20 Needham Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/14/20 JPMorgan Rubius Therapeutics resumed with a Neutral at JPMorgan 03/13/20 Morgan Stanley Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program 03/13/20 Guggenheim Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim 03/13/20 SVB Leerink Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation 09/29/20 JPMorgan Zymeworks resumed with a Neutral at JPMorgan 08/06/20 Fly Intel: Top analyst initiations 08/06/20 SVB Leerink SVB Leerink bullish on Zymeworks, initiates with an Outperform 08/06/20 SVB Leerink Zymeworks initiated with an Outperform at SVB Leerink 11/03/20 Zymeworks reports Q3 EPS ($1.43), consensus (67c) 08/05/20 Zymeworks reports Q2 EPS (77c), consensus (67c) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) 08/05/20 Sarepta reports Q2 EPS ($1.51), consensus ($1.76) 01/11/21 Sotera Health reports preliminary 2020 revenue $817M, consensus $814.05M 01/11/21 Sotera Health reports preliminary Q4 revenue $216M, consensus $206.91M 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) 11/09/20 Rubius Therapeutics reports Q3 EPS (51c), consensus (49c) 08/10/20 Rubius Therapeutics reports Q2 EPS (47c), consensus (50c) 01/07/21 Pacira reports 2020 revenue $429.6M, consensus $427.7M 10/29/20 Pacira reports Q3 adj. EPS 68c, consensus 63c 10/07/20 Pacira reports preliminary Q3 net product sales of $116.9M, consensus $111.86M 08/06/20 Pacira reports preliminary July sales of Exparel of $38.1M 10/22/20 NextGen Healthcare reinstates FY21 EPS outlook 83c-93c, consensus 83c 10/22/20 NextGen Healthcare reports Q2 EPS 30c, consensus 20c 07/30/20 NextGen Healthcare not providing FY21 guidance 07/30/20 NextGen Healthcare reports Q1 EPS 21c, consensus 8c 11/09/20 Nano-X Imaging reports Q3 EPS (29c), two est. (23c) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 08/10/20 Morphic Holding reports Q2 EPS (52c), consensus (56c) 12/07/20 HealthEquity raises FY21 EPS view to $1.55-$1.61 from $1.48-$1.58 12/07/20 HealthEquity reports Q3 EPS 41c, consensus 36c 12/07/20 Notable companies reporting after market close 09/08/20 HealthEquity sees FY21 EPS $1.48-$1.58, consensus $1.44 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 $267.53 / +15.17 (+6.01%)
10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c AGIO Agios Pharmaceuticals 11/05/20 Agios Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.31) 07/30/20 Agios Pharmaceuticals reports Q2 EPS ($1.31), consensus ($1.37) 10/29/20 Abiomed sees Q3 revenue $221M-$230M, consensus $234.29M 10/29/20 Abiomed reports Q2 EPS $1.36, consensus 92c 08/06/20 Abiomed not providing guidance due to COVID-19 08/06/20 Abiomed reports Q1 EPS 98c, consensus 29c
Conference/Events
39th Annual Healthcare…
39th Annual Healthcare Virtual Conference will be held on January 11-14.
Show Hide Related Items >> <<
12/01/20 Zymeworks expands zanidatamab trial in HER2 in amplified biliary tract cancer 11/30/20 Zymeworks gets FDA breakthrough therapy designation for zanidatamab 11/19/20 Zymeworks receives orphan drug designation for zanidatamab 11/16/20 ALX Oncology, Zymeworks partner to evaluate zanidatamab-ALX148 combo 01/07/21 Sarepta drops 52% to $80.00 after Study SRP-9001-102 results 01/07/21 Sarepta trading resumes 01/07/21 Sarepta announces Study SRP-9001-102 meets primary biological endpoint 01/07/21 Sarepta trading halted, news pending 12/18/20 Sotera Health announces debt pay down, expansion of revolving credit facility 12/22/20 Revance and Ajinomoto announce strategic commercial manufacturing agreement 12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues 01/11/21 Rubius Therapeutics announces anticipated 2021 catalysts, objectives 01/11/21 Rubius Therapeutics announces clinical program updates 12/14/20 Rubius Therapeutics trading resumes 12/14/20 Rubius Therapeutics trading halted, volatility trading pause 12/09/20 Pacira reports preliminary November net product sales $38.9M 11/18/20 Pacira receives European Commission approval for EXPAREL 11/16/20 Paulson & Co. buys Lear, cuts Tiffany in Q3 11/11/20 Pacira reports preliminary October net product sales $41.7M 10/29/20 Nano-X Imaging signs with Ambra Health to enable image access, transfer 10/02/20 Nano-X Imaging soars 33% after announcing live technology demonstration 09/23/20 Nano-X Imaging appoints Gilad Yron as CBO 09/22/20 Nano-X slides as another prominent short-seller calls it 'piece of garbage' 01/05/21 Morphic Therapeutic expands R&D collaboration with Janssen 12/04/20 Morphic Holding appoints Martin Edwards to board of directors 11/09/20 Morphic Holding expects cash to be sufficient through end of 2022 09/23/20 Morphic Holding: First volunteers dosed in Phase 1 trial of MORF-057 01/11/21 HealthEquity expects 5.7M-5.8M HSA members by Jan. 31 12/21/20 Exelixis announces cabozantinib trial meets co-primary endpoint 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/07/20 Exelixis in-licenses Aurigene's novel CDK7 inhibitor, files IND 12/02/20 Exelixis exercises option for Iconic's ADC, to develop under May 2019 pact 12/16/20 Daiichi Sankyo, Esperion announce Swissmedic approval for LDL-C treatment 12/15/20 Esperion appoints Sheldon Koenig as COO; CCO Mark Glickman to leave 11/13/20 Esperion announces results of pooled data from Phase 3 trials of NEXLETOL 10/07/20 Esperion announces results from Phase 3 trials of NEXLETOL Tablets 01/11/21 Biogen study to develop biomarkers of cognitive health using Apple devices 01/08/21 Biogen treats first patient in RESPOND study of SPINRAZA 01/05/21 Biogen, ViGeneron enter collaboration agreement to develop gene therapy products 12/22/20 LogicBio Therapeutics names Cecilia Jones as CFO, succeeding Matthias Jaffe 01/04/21 AdaptHealth falls 5% to $34.00 per share after equity offering 12/01/20 AdaptHealth, AeroCare combination to operate under AdaptHealth name 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B 12/01/20 AdaptHealth to acquire AeroCare Holdings for approximately $2B AGIO Agios Pharmaceuticals 01/11/21 Agios Pharmaceuticals expects cash to fund requirements to end of 2022 01/11/21 Agios Pharmaceuticals announces 2025 strategic vision 01/11/21 Agios Pharmaceuticals announces anticipated 2021 key milestones 12/21/20 Agios Pharmaceuticals expects results from ACTIVATE-T study in Q1 01/07/21 Abiomed surpasses more than 1,000 patents worldwide 12/21/20 Abiomed says first two patients treated with Abiomed Breethe OXY-1 System 12/15/20 Abiomed completes Impella ECP EFS first stage, gets 510 clearance for XR sheath 12/14/20 Abiomed receives 510(k) clearance from FDA for XR sheath set 12/21/20 SVB Leerink Abiomed price target raised to $320 from $280 at SVB Leerink 12/14/20 Piper Sandler Abiomed gets approval for XR sheath, says Piper Sandler 10/20/20 Piper Sandler Abiomed's TCT presentation highlights solid existing data, says Piper Sandler 08/07/20 SVB Leerink Abiomed price target raised to $335 from $280 at SVB Leerink AGIO Agios Pharmaceuticals 12/23/20 Citi Agios shares 'significantly undervalued at this point,' says Citi 12/22/20 SVB Leerink Agios Pharmaceuticals price target lowered to $51 from $61 at SVB Leerink 12/22/20 Cantor Fitzgerald Agios oncology deal a positive read to FT-4202 strategy, says Cantor Fitzgerald 12/22/20 Barclays Agios could enter 2022 with a third fewer shares, says Barclays 01/07/21 Canaccord AdaptHealth price target raised to $50 from $39 at Canaccord 12/10/20 UBS AdaptHealth initiated with a Buy at UBS 12/04/20 Deutsche Bank AdaptHealth price target raised to $47 from $36 at Deutsche Bank 12/02/20 SVB Leerink AdaptHealth price target raised to $39.50 from $32.50 at SVB Leerink 01/11/21 Credit Suisse BioAtla initiated with an Outperform at Credit Suisse 01/11/21 Jefferies BioAtla initiated with a Buy at Jefferies 01/11/21 BTIG BioAtla initiated with a Buy at BTIG 10/23/20 SVB Leerink NextGen Healthcare price target raised to $14 from $12 at SVB Leerink 10/23/20 Piper Sandler NextGen Healthcare price target lowered to $21 from $23 at Piper Sandler 07/31/20 Piper Sandler NextGen Healthcare price target raised to $23 from $17 at Piper Sandler 06/02/20 Deutsche Bank NextGen Healthcare price target lowered to $9 from $12 at Deutsche Bank 12/14/20 JPMorgan Olema Oncology initiated with an Overweight at JPMorgan 12/14/20 Jefferies Olema Pharmaceuticals initiated with a Buy at Jefferies 12/14/20 Canaccord Olema Pharmaceuticals initiated with a Buy at Canaccord 12/14/20 Cowen Olema Pharmaceuticals initiated with an Outperform at Cowen 01/06/21 RBC Capital Pacira price target raised to $70 at RBC Capital, named one of 2021 top ideas 12/14/20 Barclays Pacira price target raised to $79 from $73 at Barclays 09/30/20 Jefferies Pacira price target raised to $75 from $69 at Jefferies 09/21/20 Northland Pacira upgraded to Outperform on Exparel sales expectations at Northland 12/04/20 Mizuho Sage Therapeutics upgraded to Buy from Neutral at Mizuho 12/01/20 Truist Sage Therapeutics price target raised to $70 from $60 at Truist 12/01/20 Raymond James Sage Therapeutics downgraded to Market Perform from Outperform at Raymond James 12/01/20 Citi Sage Therapeutics price target lowered to $93 from $100 at Citi 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi 12/14/20 William Blair Calithera risk/reward attractive into CANTATA readout, says William Blair 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 01/06/21 BTIG HealthEquity initiated with a Neutral at BTIG 01/06/21 Deutsche Bank HealthEquity price target raised to $77 from $60 at Deutsche Bank 12/08/20 Cantor Fitzgerald HealthEquity price target raised to $77 from $70 at Cantor Fitzgerald 12/08/20 JPMorgan HealthEquity price target raised to $72 from $61 at JPMorgan 10/26/20 RBC Capital Morphic Holding initiated with an Outperform at RBC Capital 08/11/20 BMO Capital Morphic Holding price target raised to $37 from $30 at BMO Capital 09/15/20 Cantor Fitzgerald Cantor reiterates $70 target on Nano-X after 'unfounded' short report 09/15/20 Cantor Fitzgerald Nano-X Imaging concerns in short report unfounded, says Cantor Fitzgerald 09/15/20 Oppenheimer Nano-X Imaging initiated with a Perform at Oppenheimer 09/15/20 Berenberg Nano-X Imaging initiated with a Buy at Berenberg 01/11/21 UBS Sarepta downgraded to Neutral on 'unexpected negative' results at UBS 01/11/21 UBS Sarepta downgraded to Neutral from Buy at UBS 01/08/21 Chardan Solid Biosciences selloff on Sarepta news a buying opportunity, says Chardan 01/08/21 JPMorgan Sarepta downgraded to Underweight from Overweight at JPMorgan 12/15/20 KeyBanc Sotera Health initiated with an Overweight at KeyBanc 12/15/20 JPMorgan Sotera Health initiated with an Overweight at JPMorgan 12/15/20 Jefferies Sotera Health initiated with a Buy at Jefferies 12/15/20 Citi Sotera Health initiated with a Buy at Citi 12/29/20 Needham Needham names Collegium Pharma Top Pick for 2021, adds to Conviction List 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/14/20 JPMorgan Rubius Therapeutics resumed with a Neutral at JPMorgan 03/13/20 Morgan Stanley Morgan Stanley cuts Rubius to Equal Weight after discontinuation of PKU program 03/13/20 Guggenheim Rubius Therapeutics price target lowered to $11 from $23 at Guggenheim 03/13/20 SVB Leerink Rubius Therapeutics downgraded at SVB Leerink after RTX-134 discontinuation 09/29/20 JPMorgan Zymeworks resumed with a Neutral at JPMorgan 08/06/20 Fly Intel: Top analyst initiations 08/06/20 SVB Leerink SVB Leerink bullish on Zymeworks, initiates with an Outperform 08/06/20 SVB Leerink Zymeworks initiated with an Outperform at SVB Leerink 11/03/20 Zymeworks reports Q3 EPS ($1.43), consensus (67c) 08/05/20 Zymeworks reports Q2 EPS (77c), consensus (67c) 11/05/20 Sarepta reports Q3 EPS ($2.50), consensus ($1.71) 08/05/20 Sarepta reports Q2 EPS ($1.51), consensus ($1.76) 01/11/21 Sotera Health reports preliminary 2020 revenue $817M, consensus $814.05M 01/11/21 Sotera Health reports preliminary Q4 revenue $216M, consensus $206.91M 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) 11/09/20 Rubius Therapeutics reports Q3 EPS (51c), consensus (49c) 08/10/20 Rubius Therapeutics reports Q2 EPS (47c), consensus (50c) 01/07/21 Pacira reports 2020 revenue $429.6M, consensus $427.7M 10/29/20 Pacira reports Q3 adj. EPS 68c, consensus 63c 10/07/20 Pacira reports preliminary Q3 net product sales of $116.9M, consensus $111.86M 08/06/20 Pacira reports preliminary July sales of Exparel of $38.1M 10/22/20 NextGen Healthcare reinstates FY21 EPS outlook 83c-93c, consensus 83c 10/22/20 NextGen Healthcare reports Q2 EPS 30c, consensus 20c 07/30/20 NextGen Healthcare not providing FY21 guidance 07/30/20 NextGen Healthcare reports Q1 EPS 21c, consensus 8c 11/09/20 Nano-X Imaging reports Q3 EPS (29c), two est. (23c) 11/09/20 Morphic Holding reports Q3 EPS 17c, consensus (48c) 08/10/20 Morphic Holding reports Q2 EPS (52c), consensus (56c) 12/07/20 HealthEquity raises FY21 EPS view to $1.55-$1.61 from $1.48-$1.58 12/07/20 HealthEquity reports Q3 EPS 41c, consensus 36c 12/07/20 Notable companies reporting after market close 09/08/20 HealthEquity sees FY21 EPS $1.48-$1.58, consensus $1.44 01/10/21 Exelixis sees FY21 revenue $1.15B-$1.25B, consensus $1.16B 01/10/21 Exelixis reports preliminary Q4 revenue $270M, consensus $213.78M 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 10/21/20 Biogen cuts FY20 adjusted EPS view to $32.50-$33.50 from $34.00-$36.00 10/21/20 Biogen reports Q3 adjusted EPS $8.84, consensus $8.13 10/20/20 Notable companies reporting before tomorrow's open 12/01/20 AdaptHealth raises FY21 revenue view to $2.05B-$2.2B from $1.3B-$1.4B 11/04/20 AdaptHealth sees FY21 revenue $1.3B-$1.4B, consensus $1.21B 11/04/20 AdaptHealth raises FY20 revenue view to $1B-$1.04B from $935M-$983M 11/04/20 AdaptHealth reports Q3 EPS (4c), consensus 12c AGIO Agios Pharmaceuticals 11/05/20 Agios Pharmaceuticals reports Q3 EPS ($1.43), consensus ($1.31) 07/30/20 Agios Pharmaceuticals reports Q2 EPS ($1.31), consensus ($1.37) 10/29/20 Abiomed sees Q3 revenue $221M-$230M, consensus $234.29M 10/29/20 Abiomed reports Q2 EPS $1.36, consensus 92c 08/06/20 Abiomed not providing guidance due to COVID-19 08/06/20 Abiomed reports Q1 EPS 98c, consensus 29c
Recommendations
Needham analyst Serge…
Needham analyst Serge Belanger named Collegium Pharmaceutical (COLL) as his 2021 best idea and added the company to Needham Conviction List in place of Revance Therapeutics (RVNC), which was removed. The analyst is also keeping his Buy rating and $34 price target on Collegium. Belanger states that the growth prospects of the company's Xtampza within the "complex" opioid market remains its "key value driver" with significant sales growth expected next year, but the investment story has grown to include its "stabilized" Nucynta franchise. The analyst believes that Nucynta could contribute to Collegium's top-line growth and a "leverageable" cost structure that will further improve the company's profitability and cash generation.
Show Hide Related Items >> <<
12/22/20 Revance and Ajinomoto announce strategic commercial manufacturing agreement 12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues COLL Collegium Pharmaceutical 12/09/20 Synlogic appoints Collegium Pharmaceutical chairman Michael Heffernan to board 10/26/20 Collegium announces publication of postmarketing analysis of Xtampza ER 09/30/20 Collegium announces settlement with Teva over Xtampza ER litigation 09/25/20 Collegium Pharmaceutical appoints Rita Balice-Gordon to board of directors COLL Collegium Pharmaceutical 07/14/20 BWS Financial Collegium Pharmaceutical initiated with a Sell at BWS Financial 05/27/20 Guggenheim Guggenheim starts coverage of four pain treatment makers with two Buys 05/26/20 Guggenheim Collegium Pharmaceutical initiated with a Neutral at Guggenheim 03/23/20 Truist SunTrust lowers price targets among Pharmaceuticals due to COVID-19 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/15/20 H.C. Wainwright Revance price target raised to $33 from $27 at H.C. Wainwright 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) COLL Collegium Pharmaceutical 11/05/20 Collegium Pharmaceutical reports Q3 EPS 32c, consensus 22c 08/05/20 Collegium Pharmaceutical reports Q 2EPS 23c, consensus 20c 11/09/20 Fly Intel: After-Hours Movers
Over a month ago
Hot Stocks
Ajinomoto Bio-Pharma…
Ajinomoto Bio-Pharma Services and Revance Therapeutics announced a strategic commercial manufacturing agreement for the supply of DaxibotulinumtoxinA for Injection. DaxibotulinumtoxinA for Injection is currently under Biologics License Application (BLA) review. Aji Bio-Pharma will serve as a dual supply source and provide drug product manufacturing services for Revance at the company's aseptic manufacturing facility in San Diego, California.
Show Hide Related Items >> <<
12/17/20 Revance announces topline results from DaxibotulinumtoxinA trial 12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues 11/09/20 Revance's phase 2 trial for Daxibotulin does not meet primary efficacy endpoint 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/15/20 H.C. Wainwright Revance price target raised to $33 from $27 at H.C. Wainwright 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) 11/09/20 Fly Intel: After-Hours Movers
Hot Stocks
Revance announced topline…
Revance announced topline efficacy and safety results from its Phase 2 multicenter, open-label study of investigational drug candidate DaxibotulinumtoxinA for Injection for the combined treatment of upper facial lines, which are comprised of glabellar lines, or GL, dynamic forehead lines, or FHL, and lateral canthal lines, or LCL, commonly known as crow's feet lines. In the Phase 2 study, 48 subjects were enrolled to receive a single treatment of DaxibotulinumtoxinA for Injection with a total study duration of 36 weeks. Subjects received 40, 32, and 48 units of DaxibotulinumtoxinA for Injection respectively in the glabellar complex, forehead and lateral canthal areas. The key endpoints for efficacy were the proportion of subjects achieving a score of none or mild wrinkle severity at maximum contraction at Week 4, as assessed on the Investigator Global Assessment Frown Wrinkle Severity, or IGA-FWS, Investigator Global Assessment Forehead Wrinkle Severity, or IGA-FHWS and Investigator Global Assessment Lateral Canthal Wrinkle Severity, or IGA-LCWS, respectively. The study measured duration of effect in responders.These duration measures were defined as the median time to return to baseline wrinkle severity or the time to loss of none or mild wrinkle severity, both based on investigator and subject assessments. DaxibotulinumtoxinA for Injection was generally safe and well tolerated when all three facial areas were injected simultaneously. There were no treatment-related serious adverse events, or SAEs. The most common adverse events, or AEs, were injection site erythema, facial discomfort and headache. No eyelid or brow ptosis was reported. Participants used a 7-point Subject Global Satisfaction with Treatment Questionnaire to rate their satisfaction with treatment of DaxibotulinumtoxinA for Injection. At Week 4, 100% of participants reported being at least "Somewhat Satisfied" with the treatment in all three areas, and 83%, 78.7%, and 80.9% reported being "Very Satisfied" with the treatment of their glabellar lines, forehead lines, and crow's feet, respectively.
Show Hide Related Items >> <<
12/16/20 Revance to relocate headquarters from Silicon Valley to Nashville 11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues 11/09/20 Revance's phase 2 trial for Daxibotulin does not meet primary efficacy endpoint 11/09/20 Revance sees FY20 operating expenses $220M-$230M 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/15/20 H.C. Wainwright Revance price target raised to $33 from $27 at H.C. Wainwright 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) 11/09/20 Fly Intel: After-Hours Movers
Hot Stocks
Tennessee Gov. Bill Lee,…
Tennessee Gov. Bill Lee, Department of Economic and Community Development Commissioner Bob Rolfe and Revance Therapeutics officials announced that the company will relocate its headquarters from Silicon Valley's Newark, California, to Nashville, Tennessee.
Show Hide Related Items >> <<
11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues 11/09/20 Revance's phase 2 trial for Daxibotulin does not meet primary efficacy endpoint 11/09/20 Revance sees FY20 operating expenses $220M-$230M 11/09/20 Revance reports Q3 EPS ($1.34), consensus ($1.03) 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/15/20 H.C. Wainwright Revance price target raised to $33 from $27 at H.C. Wainwright 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) 11/09/20 Fly Intel: After-Hours Movers
Conference/Events
Virtual Meeting to be…
Virtual Meeting to be held on December 7 hosted by Mizuho.
Show Hide Related Items >> <<
11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues 11/09/20 Revance's phase 2 trial for Daxibotulin does not meet primary efficacy endpoint 11/09/20 Revance sees FY20 operating expenses $220M-$230M 11/09/20 Revance reports Q3 EPS ($1.34), consensus ($1.03) 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/15/20 H.C. Wainwright Revance price target raised to $33 from $27 at H.C. Wainwright 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) 11/09/20 Fly Intel: After-Hours Movers
Conference/Events
Virtual Meeting to be…
Virtual Meeting to be held on December 7 hosted by Mizuho.
Show Hide Related Items >> <<
11/25/20 FDA defers decision on BLA for 'frown' lines treatment due to Covid issues 11/09/20 Revance's phase 2 trial for Daxibotulin does not meet primary efficacy endpoint 11/09/20 Revance sees FY20 operating expenses $220M-$230M 11/09/20 Revance reports Q3 EPS ($1.34), consensus ($1.03) 11/25/20 H.C. Wainwright H.C. Wainwright keeps Buy rating on Revance, says FDA news 'not surprising' 11/10/20 Mizuho Revance price target lowered to $30 from $32 at Mizuho 10/26/20 Barclays Revance price target raised to $38 from $35 at Barclays 10/15/20 H.C. Wainwright Revance price target raised to $33 from $27 at H.C. Wainwright 08/06/20 Revance reports Q2 EPS ($1.12), consensus ($1.01) 11/09/20 Fly Intel: After-Hours Movers